12/19
09:09 am
mrvi
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock.
Low
Report
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Guggenheim. They set a "neutral" rating on the stock.
12/5
04:05 pm
mrvi
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
Low
Report
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
12/5
08:01 am
mrvi
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $4.25 price target on the stock.
Low
Report
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) was downgraded by analysts at The Goldman Sachs Group, Inc. from a "neutral" rating to a "sell" rating. They now have a $4.25 price target on the stock.
12/5
07:02 am
mrvi
Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer [Yahoo! Finance]
Low
Report
Industry Veteran and Gene Therapy Manufacturing Expert, Ray Kaczmarek, Joins Nanoscope as Chief Technical and Manufacturing Officer [Yahoo! Finance]
11/14
08:09 am
mrvi
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
Medium
Report
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) is now covered by analysts at Wolfe Research. They set a "peer perform" rating on the stock.
11/12
08:05 am
mrvi
Maravai LifeSciences Announces November 2024 Investor Conference Schedule
Medium
Report
Maravai LifeSciences Announces November 2024 Investor Conference Schedule
11/10
08:50 am
mrvi
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price [Yahoo! Finance]
High
Report
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price [Yahoo! Finance]
11/8
01:45 pm
mrvi
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) had its price target lowered by analysts at Royal Bank of Canada from $17.00 to $13.00. They now have an "outperform" rating on the stock.
Medium
Report
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) had its price target lowered by analysts at Royal Bank of Canada from $17.00 to $13.00. They now have an "outperform" rating on the stock.
11/8
03:32 am
mrvi
Maravai LifeSciences (MRVI) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
High
Report
Maravai LifeSciences (MRVI) Q3 2024 Earnings Call Transcript [Yahoo! Finance]
11/8
02:48 am
mrvi
Maravai LifeSciences Holdings Inc (MRVI) Q3 2024 Earnings Call Highlights: Navigating ... [Yahoo! Finance]
High
Report
Maravai LifeSciences Holdings Inc (MRVI) Q3 2024 Earnings Call Highlights: Navigating ... [Yahoo! Finance]
11/7
04:18 pm
mrvi
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research [Yahoo! Finance]
High
Report
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research [Yahoo! Finance]
11/7
04:01 pm
mrvi
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research
High
Report
Maravai LifeSciences Plans to Acquire DNA and RNA Business of Officinae Bio, Advancing Support for Innovative Nucleic Acid Research
11/7
04:01 pm
mrvi
Maravai LifeSciences Reports Third Quarter 2024 Financial Results
High
Report
Maravai LifeSciences Reports Third Quarter 2024 Financial Results
10/15
04:05 pm
mrvi
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024
Low
Report
Maravai LifeSciences To Host Earnings Conference Call on Thursday, November 7, 2024
10/8
10:31 am
mrvi
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $8.00 to $7.00. They now have a "neutral" rating on the stock.
Low
Report
Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI) had its price target lowered by analysts at The Goldman Sachs Group, Inc. from $8.00 to $7.00. They now have a "neutral" rating on the stock.
10/1
09:30 am
mrvi
Codexis licenses Genomics Life Science enzyme portfolio to Alphazyme LLC [Seeking Alpha]
Low
Report
Codexis licenses Genomics Life Science enzyme portfolio to Alphazyme LLC [Seeking Alpha]